Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.

Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH.

Lancet. 2015 Oct 31;386(10005):1754-64. doi: 10.1016/S0140-6736(15)60031-9. Epub 2015 Aug 4.

PMID:
26466871
2.

Tasimelteon: a selective and unique receptor binding profile.

Lavedan C, Forsberg M, Gentile AJ.

Neuropharmacology. 2015 Apr;91:142-7. doi: 10.1016/j.neuropharm.2014.12.004. Epub 2014 Dec 19.

3.

Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.

Thompson A, Lavedan C, Volpi S.

Psychiatry Res. 2010 Feb 28;175(3):271-3. doi: 10.1016/j.psychres.2009.03.020. Epub 2009 Dec 31.

PMID:
20045196
4.

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.

Volpi S, Potkin SG, Malhotra AK, Licamele L, Lavedan C.

J Clin Psychiatry. 2009 Jun;70(6):801-9.

PMID:
19573479
5.

Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia.

Polymeropoulos MH, Licamele L, Volpi S, Mack K, Mitkus SN, Carstea ED, Getoor L, Thompson A, Lavedan C.

Schizophr Res. 2009 Mar;108(1-3):134-42. doi: 10.1016/j.schres.2008.11.025. Epub 2009 Jan 15.

PMID:
19150222
6.

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.

Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, Licamele L, Polymeropoulos MH, Lavedan C.

Mol Psychiatry. 2009 Nov;14(11):1024-31. doi: 10.1038/mp.2008.52. Epub 2008 Jun 3.

PMID:
18521091
7.

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.

Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH.

Mol Psychiatry. 2009 Aug;14(8):804-19. doi: 10.1038/mp.2008.56. Epub 2008 Jun 3.

PMID:
18521090
8.

Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.

Lavedan C, Volpi S, Polymeropoulos MH, Wolfgang CD.

Pharmacogenomics. 2008 Mar;9(3):289-301. doi: 10.2217/14622416.9.3.289.

PMID:
18303965
9.

A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration.

Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MH.

Neurosci Lett. 2002 Mar 29;322(1):57-61.

PMID:
11958843
10.

Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies.

Dressman MA, Walz TM, Lavedan C, Barnes L, Buchholtz S, Kwon I, Ellis MJ, Polymeropoulos MH.

Pharmacogenomics J. 2001;1(2):135-41.

PMID:
11911440
11.

Absence of mutation in the beta- and gamma-synuclein genes in familial autosomal dominant Parkinson's disease.

Lavedan C, Buchholtz S, Auburger G, Albin RL, Athanassiadou A, Blancato J, Burguera JA, Ferrell RE, Kostic V, Leroy E, Leube B, Mota-Vieira L, Papapetropoulos T, Pericak-Vance MA, Pinkus J, Scott WK, Ulm G, Vasconcelos J, Vilchez JJ, Nussbaum RL, Polymeropoulos MH.

DNA Res. 1998 Dec 31;5(6):401-2. No abstract available.

PMID:
10048491
12.

Deletions in the Parkin gene and genetic heterogeneity in a Greek family with early onset Parkinson's disease.

Leroy E, Anastasopoulos D, Konitsiotis S, Lavedan C, Polymeropoulos MH.

Hum Genet. 1998 Oct;103(4):424-7.

PMID:
9856485
13.

Genomic organization and expression of the human beta-synuclein gene (SNCB).

Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S, Nussbaum RL, Polymeropoulos MH.

Genomics. 1998 Nov 15;54(1):173-5.

PMID:
9806846
14.

The ubiquitin pathway in Parkinson's disease.

Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH.

Nature. 1998 Oct 1;395(6701):451-2. No abstract available.

PMID:
9774100
15.

The synuclein family.

Lavedan C.

Genome Res. 1998 Sep;8(9):871-80. Review.

16.

Identification, localization and characterization of the human gamma-synuclein gene.

Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL, Polymeropoulos MH.

Hum Genet. 1998 Jul;103(1):106-12.

PMID:
9737786
17.
18.

Contig map of the Parkinson's disease region on 4q21-q23.

Lavedan C, Dehejia A, Pike B, Dutra A, Leroy E, Ide SE, Root H, Rubenstein J, Boyer RL, Chandrasekharappa S, Makalowska I, Nussbaum RL, Polymeropoulos MH.

DNA Res. 1998 Feb 28;5(1):19-23.

PMID:
9628579
19.

Trinucleotide repeats (CGG)22TGG(CGG)43TGG(CGG)21 from the fragile X gene remain stable in transgenic mice.

Lavedan CN, Garrett L, Nussbaum RL.

Hum Genet. 1997 Sep;100(3-4):407-14.

PMID:
9272164
20.

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL.

Science. 1997 Jun 27;276(5321):2045-7.

21.

Mutations in American families with spinocerebellar ataxia (SCA) type 3: SCA3 is allelic to Machado-Joseph disease.

Higgins JJ, Nee LE, Vasconcelos O, Ide SE, Lavedan C, Goldfarb LG, Polymeropoulos MH.

Neurology. 1996 Jan;46(1):208-13.

PMID:
8559377
22.

French myotonic dystrophy families show expansion of a CTG repeat in complete linkage disequilibrium with an intragenic 1 kb insertion.

Lavedan C, Hofmann-Radvanyi H, Boileau C, Bonaïti-Pellié C, Savoy D, Shelbourne P, Duros C, Rabes JP, Dehaupas I, Luce S, et al.

J Med Genet. 1994 Jan;31(1):33-6.

23.

Myotonic dystrophy: absence of CTG enlarged transcript in congenital forms, and low expression of the normal allele.

Hofmann-Radvanyi H, Lavedan C, Rabès JP, Savoy D, Duros C, Johnson K, Junien C.

Hum Mol Genet. 1993 Aug;2(8):1263-6.

PMID:
7691346
24.

Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism.

Lavedan C, Hofmann-Radvanyi H, Shelbourne P, Rabes JP, Duros C, Savoy D, Dehaupas I, Luce S, Johnson K, Junien C.

Am J Hum Genet. 1993 May;52(5):875-83.

25.

Different sex-dependent constraints in CTG length variation as explanation for congenital myotonic dystrophy.

Lavedan C, Hofmann-Radvanyi H, Rabes JP, Roume J, Junien C.

Lancet. 1993 Jan 23;341(8839):237. No abstract available.

PMID:
8093513
26.

NcoI RFLP at 19q13 identified by the DNA sequence pW119B (D19S169).

Lavedan C, Savoy D, Simon M, Wieringa B, Junien C.

Nucleic Acids Res. 1991 Oct 25;19(20):5804. No abstract available.

27.

Prenatal diagnosis of myotonic dystrophy using closely linked flanking markers.

Lavedan C, Hofmann H, Shelbourne P, Duros C, Savoy D, Johnson K, Junien C.

J Med Genet. 1991 Feb;28(2):89-91.

28.

[Antioncogenes: models for tumors in children].

Junien C, Henry I, Jeanpierre C, Lavedan C, Antignac C, Puech A, Beroud C.

Bull Cancer. 1991 Jan;78(1):57-68. French.

PMID:
2021687
29.

Direct haplotyping by double digestion of PCR-amplified creatine kinase (CKMM): application to myotonic dystrophy diagnosis.

Lavedan C, Duros C, Savoy D, Leblond S, Bailly J, Korneluk R, Junien C.

Genomics. 1990 Dec;8(4):739-40. No abstract available.

PMID:
1980487
30.

Constitutional and somatic deletions of two different regions of maternal chromosome 11 in Wilms tumor.

Jeanpierre C, Antignac C, Beroud C, Lavedan C, Henry I, Saunders G, Williams B, Glaser T, Junien C.

Genomics. 1990 Jul;7(3):434-8.

PMID:
1973142
31.

Molecular definition of de novo and genetically transmitted WAGR-associated rearrangements of 11p13.

Lavedan C, Barichard F, Azoulay M, Couillin P, Molina Gomez D, Nicolas H, Quack B, Rethoré MO, Noel B, Junien C.

Cytogenet Cell Genet. 1989;50(2-3):70-4.

PMID:
2570677

Supplemental Content

Loading ...
Support Center